Literature DB >> 12397581

Contributions of endothelin-1 and sodium hydrogen exchanger-1 in the diabetic myocardium.

Denise Hileeto1, Mark Cukiernik, Suranjana Mukherjee, Terry Evans, Yousef Barbin, Donal Downey, Morris Karmazyn, Subrata Chakrabarti.   

Abstract

BACKGROUND: Endothelin-1 (ET-1) and sodium hydrogen exchanger-1 (NHE-1) are important mediators of several disease processes affecting the heart, especially relating to myocardial ischemia. There is evidence that their actions may be interrelated. Their contributions to diabetic heart disease have not been extensively documented. Accordingly, the aim of this study was to investigate the interactive roles of ET-1 and NHE-1 in the pathogenesis of diabetic cardiomyopathy, a significant cause of morbidity in diabetic patients.
METHODS: Streptozotocin-induced diabetic Sprague Dawley rats were treated with NHE-1 blocker cariporide or dual ET(A)/ET(B) blocker bosentan and were subsequently studied one, three and six months after induction of diabetes. These animals were compared with nondiabetic rats as well as with diabetic rats on poor blood glucose control.
RESULTS: Diabetes leads to hyperglycemia, reduced body weight gain and increased glycated hemoglobin levels. These animals exhibited focal myocardial fibrosis and increased ejection fraction, in association with a tendency to increased left ventricular wall thickness and heart weight, after six months of follow-up, both bosentan and cariporide prevented these responses. Diabetes also caused significant increases in ET-1 mRNA and protein expression in the heart at all time points, which was further augmented by cariporide treatment for three months. Diabetes did not affect either mRNA or protein expression of NHE-1, although these did decrease in hearts of diabetic animals treated with bosentan for six months.
CONCLUSIONS: These results indicate an important contribution of both ET-1 and NHE-1 in the pathogenesis of diabetic cardiomyopathy. These data suggest that NHE-1 may act as a downstream mediator in the production of ET-induced functional and structural changes in the myocardium in diabetes. Copyright 2002 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12397581     DOI: 10.1002/dmrr.322

Source DB:  PubMed          Journal:  Diabetes Metab Res Rev        ISSN: 1520-7552            Impact factor:   4.876


  17 in total

1.  Increased cation conductance in human erythrocytes artificially aged by glycation.

Authors:  Yuliya V Kucherenko; Shefalee K Bhavsar; Valentin I Grischenko; Uwe R Fischer; Stephan M Huber; Florian Lang
Journal:  J Membr Biol       Date:  2010-06-06       Impact factor: 1.843

Review 2.  Mechanisms of subcellular remodeling in heart failure due to diabetes.

Authors:  Naranjan S Dhalla; Nobuakira Takeda; Delfin Rodriguez-Leyva; Vijayan Elimban
Journal:  Heart Fail Rev       Date:  2014-01       Impact factor: 4.214

3.  Endothelin-1 receptor blockade prevented the electrophysiological dysfunction in cardiac myocytes of streptozotocin-induced diabetic rats.

Authors:  Yanfeng Ding; Ruijiao Zou; Robert L Judd; Juming Zhong
Journal:  Endocrine       Date:  2006-08       Impact factor: 3.633

4.  Cardiac metallothionein synthesis in streptozotocin-induced diabetic mice, and its protection against diabetes-induced cardiac injury.

Authors:  Ye Song; Jianxun Wang; Yan Li; Yibo Du; Gavin E Arteel; Jack T Saari; Y James Kang; Lu Cai
Journal:  Am J Pathol       Date:  2005-07       Impact factor: 4.307

5.  Cardioprotective effects of atrasentan, an endothelin-A receptor antagonist, but not of nitric oxide in diabetic mice with myocyte-specific overexpression of endothelial nitric oxide synthase.

Authors:  Gerald Wölkart; Heike Stessel; Zora Saad; Michael Kirchengast; Friedrich Brunner
Journal:  Br J Pharmacol       Date:  2006-05-15       Impact factor: 8.739

6.  Chronic endothelin-A receptor antagonism is as protective as angiotensin converting enzyme inhibition against cardiac dysfunction in diabetic rats.

Authors:  G Wölkart; X Pang; H Stessel; M Kirchengast; F Brunner
Journal:  Br J Pharmacol       Date:  2007-06-18       Impact factor: 8.739

Review 7.  NHE-1 inhibition: from protection during acute ischaemia/reperfusion to prevention/reversal of myocardial remodelling.

Authors:  Wolfgang J Linz; Andreas E Busch
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-09-19       Impact factor: 3.000

8.  Improvement in cardiac function of diabetic rats by bosentan is not associated with changes in the activation of PKC isoforms.

Authors:  Jihong Jiang; Violet Yuen; Hong Xiang; John H McNeill
Journal:  Mol Cell Biochem       Date:  2006-01       Impact factor: 3.842

9.  Role of differential signaling pathways and oxidative stress in diabetic cardiomyopathy.

Authors:  Kenichi Watanabe; Rajarajan A Thandavarayan; Meilei Harima; Flori R Sari; Narasimman Gurusamy; Punniyakoti T Veeraveedu; Sayaka Mito; Wawaimuli Arozal; Vijayakumar Sukumaran; Arun Prasath Laksmanan; Vivian Soetikno; Makoto Kodama; Yoshifusa Aizawa
Journal:  Curr Cardiol Rev       Date:  2010-11

10.  TRC120038, a Novel Dual AT(1)/ET(A) Receptor Blocker for Control of Hypertension, Diabetic Nephropathy, and Cardiomyopathy in ob-ZSF1 Rats.

Authors:  Anookh Mohanan; Ram Gupta; Amita Dubey; Vikrant Jagtap; Appaji Mandhare; Ramesh C Gupta; Vijay Chauthaiwale; Chaitanya Dutt
Journal:  Int J Hypertens       Date:  2011-12-22       Impact factor: 2.420

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.